Skip to main content

Table 2 Biomarker expression among screening-detected cancers (n = 1,297) and distinct categories of interval cancers (n = 948)

From: Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain

 

Screening-detected cancers

True interval cancers

False negatives

Minimal-sign cancers

Occult tumors

 
 

n = 1,297

n = 455

n = 224

n = 166

n = 103

P-value

Estrogen receptor

1022 (82.5)*

283 (63.2 )*

178 (81.7)

114 (71.3)

84 (88.4)

<0.001

 Missing values

58

7

6

6

8

 

Progesterone receptor

775 (63.7)*

214 (48.2)*

128 (59.0)

86 (54.4)

60 (64.5)

<0.001

 Missing values

81

11

7

8

10

 

HER2

203 (21.9)

113 (29.1)*

44 (24.0)

31 (23.1)

11 (14.1)

0.018

 Missing values

371

67

41

32

25

 

p53

149 (22.7)

86 (36.6)*

23 (21.5)

27 (34.6)

17 (28.8)

<0.001

 Missing values

641

228

117

88

44

 

Ki67

381 (40.2)

169 (52.5 )*

83 (50.3)

50 (41.7)

26 (39.4)

0.001

 Missing values

349

133

59

46

37

 
  1. Number of cases and percentage of tumors with positive biomarker expression. *Standardized Pearson residuals with statistically significant deviation between observed and expected values. P-values for comparison of characteristics among the five study groups were obtained by two-sided Chi-square test. HER2, human epidermal growth factor receptor 2.